Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Dexamethasone phosphate
Drug ID BADD_D00624
Description Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions.[L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.[L14318]
Indications and Usage
Intranasal aerosol: for the treatment of allergic ot inflammatory nasal conditions, and nasal polyps
Marketing Status Prescription; Discontinued
ATC Code A01AC02; C05AA09; D07AB19; D07XB05; D10AA03; H02AB02; R01AD03; S01BA01; S01CB01; S02BA06; S03BA01
DrugBank ID DB01234
KEGG ID D07802
MeSH ID C004180
PubChem ID 9400
TTD Drug ID D0NA8U
NDC Product Code 0009-5019; 55718-157; 42195-270; 47781-914; 47781-916; 55700-961; 63629-4127; 63629-7850; 67296-0326; 68071-4127; 0054-8183; 46439-8765; 51552-0430; 55718-133; 48102-050; 48102-051; 51407-361; 61919-827; 68788-7142; 70518-2998; 0054-4184; 0054-4186; 49452-2465; 57582-031; 65089-0045; 42195-127; 55289-903; 60219-2043; 60219-2044; 63187-561; 64980-509; 69306-111; 69306-114; 0054-4181; 0054-8175; 71161-138; 79572-012; 82298-111; 43063-266; 63629-3742; 63629-4129; 68071-2321; 68788-7267; 0054-4182; 0054-8176; 52128-170; 50090-0089; 50090-0090; 50090-0091; 63629-7806; 69306-112; 71205-012; 0054-4180; 0054-8174; 51927-1081; 0998-0615; 42195-490; 45865-989; 48102-052; 49999-059; 0023-3348; 55289-582; 55700-854; 0054-4179; 72189-254; 72893-015; 0395-8142; 22552-0039; 55718-156; 42195-721; 48102-047; 48102-049; 61919-269; 70382-204; 0054-3177; 71205-013; 0054-8179; 79043-200; 0121-0907; 55154-4914; 0054-8181; 71879-001; 60722-3013; 15014-211; 42195-121; 42195-151; 60432-466; 63187-383; 67296-1413; 70518-1534; 0054-4183; 0054-8180; 38779-0405; 0121-1814; 42195-149; 42195-221; 50090-0088; 54879-003; 55154-4901; 70518-3050
Synonyms dexamethasone 21-phosphate | dexamethasone phosphate | dexamethasone 21-phosphate, monosodium salt, (11beta,16alpha)-isomer | dexamethasone sodium phosphate | dexamethasonedisodium phosphate | dexamethasone phosphate disodium salt | Solu- Decadron | Spersadex | Spersadox | dexamethasone 21-phosphate, (6alpha,11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, disodium salt, (6alpha,11beta,16alpha)-isomer | Decadron phosphate | dexamethasone 21-phosphate, sodium salt, (11beta,16alpha)-isomer | dexamethasone 21-phosphate, copper (+2) salt (2:3), (11beta,16alpha)-isomer
Chemical Information
Molecular Formula C22H30FO8P
CAS Registry Number 312-93-6
SMILES CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)COP(=O)(O)O)O)C)O)F)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Osteoarthritis15.01.04.001--Not Available
Osteonecrosis24.04.05.004; 15.02.04.007--
Osteoporosis15.02.03.002; 14.04.04.002--
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Pancreatitis acute07.18.01.002--Not Available
Papilloedema06.09.02.002; 24.03.07.001; 17.07.02.004--
Paraesthesia17.02.06.005--
Pathological fracture16.32.03.007; 15.08.02.008; 12.04.02.006--Not Available
Peptic ulcer07.04.07.001--Not Available
Petechiae24.07.06.004; 01.01.03.002; 23.06.01.003--Not Available
Retinopathy of prematurity18.04.01.004; 12.01.04.009; 06.09.01.004--Not Available
Schizophrenia19.03.04.001--Not Available
Secondary adrenocortical insufficiency14.11.01.014; 05.01.02.003--Not Available
Seizure17.12.03.001--
Skin atrophy23.01.05.001--
Skin exfoliation23.03.07.003--Not Available
Skin hyperpigmentation23.05.01.003--
Skin striae23.01.05.002--Not Available
Small intestinal perforation07.04.06.006--
Sodium retention14.05.04.003--Not Available
Spinal compression fracture15.08.05.004; 14.04.04.003; 12.04.04.001--Not Available
Steroid withdrawal syndrome19.04.02.014; 08.06.02.013; 05.01.02.007--Not Available
Suicidal ideation19.12.01.003--
Telangiectasia24.03.03.003; 23.06.03.001--
Tendon rupture15.07.01.008; 12.01.07.003--Not Available
Tuberculosis11.04.01.006--Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vasculitis24.05.02.001; 10.02.02.006--
Vertigo17.02.12.002; 04.04.01.003--
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages